Your browser doesn't support javascript.
loading
Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness.
Schuster, Randi Melissa; Fontaine, Madeleine; Nip, Emily; Zhang, Haiyue; Hanly, Ailish; Evins, A Eden.
Afiliação
  • Schuster RM; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: Rschuster@mgh.harvard.edu.
  • Fontaine M; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Nip E; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Zhang H; Department of Biostatistics, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Hanly A; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; University of Massachusetts Medical School, Worcester, MA, USA.
  • Evins AE; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Prev Med ; 104: 40-45, 2017 11.
Article em En | MEDLINE | ID: mdl-28242263
ABSTRACT
Young adults with psychiatric illnesses are more likely to use cannabis and experience problems from use. It is not known whether those with a lifetime psychiatric illness experience a prolonged cannabis withdrawal syndrome with abstinence. Participants were fifty young adults, aged 18-25, recruited from the Boston-area in 2015-2016, who used cannabis at least weekly, completed the Structured Clinical Interview for DSM-IV to identify Axis I psychiatric diagnoses (PD+ vs PD-), and attained cannabis abstinence with a four-week contingency management protocol. Withdrawal symptom severity was assessed at baseline and at four weekly abstinent visits using the Cannabis Withdrawal Scale. Cannabis dependence, age of initiation, and rate of abstinence were similar in PD+ and PD- groups. There was a diagnostic group by abstinent week interaction, suggesting a difference in time course for resolution of withdrawal symptoms by group, F(4,46)=3.8, p=0.009, controlling for sex, baseline depressive and anxiety symptoms, and frequency of cannabis use in the prior 90days. In post hoc analyses, there was a difference in time-course of cannabis withdrawal. PD- had significantly reduced withdrawal symptom severity in abstinent week one [t(46)=-2.2, p=0.03], while PD+ did not report improved withdrawal symptoms until the second abstinent week [t(46)=-4.1, p=0.0002]. Cannabis withdrawal symptoms improved over four weeks in young people with and without a lifetime psychiatric diagnosis. However, those with a psychiatric illness reported one week delayed improvement in withdrawal symptom severity. Longer duration of cannabis withdrawal may be a risk factor for cannabis dependence and difficulty quitting.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Cannabis / Transtornos Mentais Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Cannabis / Transtornos Mentais Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article